Next Article in Journal
Food Neophobia in Celiac Disease and Other Gluten-Free Diet Individuals
Next Article in Special Issue
Xylitol’s Health Benefits beyond Dental Health: A Comprehensive Review
Previous Article in Journal
Comprehensive Approaches to Improving Nutrition: Future Prospects
Previous Article in Special Issue
Gut Microbiome: Profound Implications for Diet and Disease
Article

Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study

1
Endocrinology and Nutrition Clinical Management Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain
2
Endocrinology and Nutrition Clinical Management Unit, University Hospital of Jaén, 23007 Jaén, Spain
3
Department of Health Sciences, School of Health Sciences, University of Jaén, 23071 Jaén, Spain
4
Digestive Diseases Clinical Management Unit, University Hospital of Jaén, 23007 Jaén, Spain
5
Department of Signal Theory, Networking, and Communications, University of Granada, 18071 Granada, Spain
6
Department of Microbiology, University Hospital Campus de la Salud, 18016 Granada, Spain
7
Instituto de Investigación Biosanitaria ibs. GRANADA, 18012 Granada, Spain
8
Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain
9
Institute of Nutrition and Food Technology “José Mataix”, Center of Biomedical Research, University of Granada, 18016 Granada, Spain
10
CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain
11
Biosearch Life, 18004 Granada, Spain
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(8), 1761; https://doi.org/10.3390/nu11081761
Received: 27 June 2019 / Revised: 16 July 2019 / Accepted: 29 July 2019 / Published: 31 July 2019
(This article belongs to the Special Issue Nutrition, Microbiota and Noncommunicable Diseases)
Previous studies have reported that probiotics may improve clinical and inflammatory parameters in patients with obesity and metabolic syndrome (MetS). Lactobacillus (L.) reuteri V3401 has shown promising results on the components of MetS in animal studies. We aimed to evaluate the effects of L. reuteri V3401 together with healthy lifestyle recommendations on adult patients with MetS. Methods: We carried out a randomized, crossover, placebo-controlled, single-center trial in which we included 53 adult patients newly diagnosed with MetS. Patients were block randomly allocated by body mass index (BMI) and sex to receive a capsule containing either the probiotic L. reuteri V3401 (5 × 109 colony-forming units) or a placebo once daily for 12 weeks. Anthropometric variables, biochemical and inflammatory biomarkers, as well as the gastrointestinal microbiome composition were determined. Results: There were no differences between groups in the clinical characteristics of MetS. However, we found that interleukin-6 (IL-6) and soluble vascular cell adhesion molecule 1 (sVCAM-1) diminished by effect of the treatment with L. reuteri V3401. Analysis of the gastrointestinal microbiome revealed a rise in the proportion of Verrucomicrobia. Conclusions: Consumption of L. reuteri V3401 improved selected inflammatory parameters and modified the gastrointestinal microbiome. Further studies are needed to ascertain additional beneficial effects of other probiotic strains in MetS as well as the mechanisms by which such effects are exerted. View Full-Text
Keywords: metabolic syndrome; gastrointestinal microbiome; Lactobacillus reuteri V3401; probiotics; obesity metabolic syndrome; gastrointestinal microbiome; Lactobacillus reuteri V3401; probiotics; obesity
Show Figures

Figure 1

MDPI and ACS Style

Tenorio-Jiménez, C.; Martínez-Ramírez, M.J.; Del Castillo-Codes, I.; Arraiza-Irigoyen, C.; Tercero-Lozano, M.; Camacho, J.; Chueca, N.; García, F.; Olza, J.; Plaza-Díaz, J.; Fontana, L.; Olivares, M.; Gil, Á.; Gómez-Llorente, C. Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. Nutrients 2019, 11, 1761. https://doi.org/10.3390/nu11081761

AMA Style

Tenorio-Jiménez C, Martínez-Ramírez MJ, Del Castillo-Codes I, Arraiza-Irigoyen C, Tercero-Lozano M, Camacho J, Chueca N, García F, Olza J, Plaza-Díaz J, Fontana L, Olivares M, Gil Á, Gómez-Llorente C. Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. Nutrients. 2019; 11(8):1761. https://doi.org/10.3390/nu11081761

Chicago/Turabian Style

Tenorio-Jiménez, Carmen, María J. Martínez-Ramírez, Isabel Del Castillo-Codes, Carmen Arraiza-Irigoyen, Mercedes Tercero-Lozano, José Camacho, Natalia Chueca, Federico García, Josune Olza, Julio Plaza-Díaz, Luis Fontana, Mónica Olivares, Ángel Gil, and Carolina Gómez-Llorente. 2019. "Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study" Nutrients 11, no. 8: 1761. https://doi.org/10.3390/nu11081761

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop